secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001437749-24-022354
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

European patent granted covering brilaroxazine for pulmonary hypertension; adds to US, China, Japan patents
--------------------------------------------------------------------------------

- European Patent EP3244896 granted covering brilaroxazine for treating PH, PAH, including PH in COPD or SCD patients.
- Similar patents already granted in United States, China, and Japan for brilaroxazine in PH/PAH.
- Brilaroxazine has Orphan Drug Designation from FDA for treatment of pulmonary arterial hypertension.
- CEO cites anti-inflammatory/antifibrotic activity in animal models; plans to evaluate PH/PAH expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924022354/0001437749-24-022354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924022354/rvph20240709_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer